** LTR Pharma LTP.AX rises as much as 7.5% to A$0.50, highest since November 27
** Biopharmaceutical firm gets regulatory clearance from Therapeutic Goods Administration for its SPONTAN Phase II clinical study
** Says study expected to generate prescribing insights for physicians treating older men
** About 478,000 shares traded, 1.9x the 30-day avg
** LTP last up 3.2%, trimming YTD losses to 40.7%
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.